2.43%XLF 15.10 
10.30%QQQQ 31.32 0.63%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
MEMPHIS, Tenn. - Biopharmaceutical company GTx Inc. said Monday it expected to report a full-year loss between $52 million and $62 million -larger than the $44.7 million loss expected by Wall Street.
| GTXI | 14.97 |  -0.46 |
The company said that its projection includes prelaunch costs for lead candidate Acapodene, which is designed to treat side effects of androgen deprivation therapy, which is commonly used in prostate cancer treatment.
However, the estimate does not include prelaunch costs for a second Acapodene indication to treat prostate cancer.
GTx anticipates filing an application with the Food and Drug Administration in the summer for Acapodene in the androgen deprivation therapy indication with a potential launch in 2009.
As the presidential race revs up, political conversations in NFL locker rooms echo those in workplaces nationwide. Taxes. Economy. McCain. Obama....
Intimate photos taken by Brad Pitt of girlfriend Angelina Jolie breastfeeding on...
In last week's report, I held out the prospect that the US government rescue package might result in a change in sentiment in financial mark...
|
Professional Website Design For Corporate - Get a Free Quote Today
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
